Core Viewpoint - Opus Genetics, Inc. is gaining attention as a promising investment opportunity due to its innovative gene therapy programs aimed at treating inherited retinal diseases, particularly with the initiation of coverage by Piper Sandler with an "Overweight" rating and a price target of $7 [2]. Financial Performance - For Q3 2025, Opus Genetics reported a net loss of $17.5 million, an increase from $7.5 million in the same quarter of the previous year, primarily due to changes in the fair value of warrants [3]. - The company completed a $23 million equity offering to support its clinical trials, including the ongoing Phase 1/2 trial for OPGx-BEST1 [4]. Product Development - The lead gene therapy program, OPGx-LCA5, aims to treat Leber congenital amaurosis type 5 (LCA5), a condition with no current treatment options, and has shown significant improvements in vision for pediatric patients in Phase 1/2 trials [2][3]. - Opus Genetics successfully completed a Type B Regenerative Medicine Advanced Therapy (RMAT) meeting with the FDA, which may facilitate an accelerated regulatory pathway for OPGx-LCA5 approval [4]. Market Position - The company is focused on developing gene therapies to restore vision in patients with inherited retinal diseases, positioning itself as a key player in this niche market [5].
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT